Abstract
Objective The immune system plays a key role in protecting against cancer. Increased immune infiltration in tumor tissue is usually associated with improved clinical outcome, but in colorectal cancer (CRC), excessive immune infiltration has also been shown to lead to worst prognosis. The factors underlying this immune overdrive phenotype remains unknown.
Design Using RNA sequencing data from The Cancer Genome Atlas, the expression of over 1,000 transposable element (TE) subfamilies were quantified using the “REdiscoverTE” pipeline. Candidate prognostic and immunogenic TEs were screened by survival and correlation analysis, respectively. Based on these candidates, a TE expression score was developed and CRC patients were clustered using the “kaps” algorithm.
Results In CRC, we found that the TE expression score stratified patients into four clusters each with distinctive prognosis. Those with the highest TE expression were associated with immune overdrive and had the poorest outcomes. Importantly, this association was independent of microsatellite instability status and tumor mutation burden. To link TE overexpression to the immune overdrive phenotype, we showed that cell lines treated with DNA methyltransferase inhibitors also had a high TE expression score and activation of cellular innate immune response pathways. Finally, a pan-cancer survey of TE expression identified a subset of kidney renal clear cell carcinoma with a similar adverse immune overdrive phenotype with poor prognosis.
Conclusion Our findings reveal that TE expression is associated with immune overdrive in cancer and is an independent predictor of immune infiltration and prognosis in CRC patients.
What is already known about this subject?
Cancers with high immune infiltration generally have better prognosis, but it is unknown why a subset of colorectal cancers (CRC) with high immune infiltration have the poorest outcomes.
Transposable element (TE) expression has been shown to be strongly associated with immune infiltration in cancers but its role in patient prognosis is unclear.
TEs can be reactivated by DNA hypomethylation in cancers, resulting in immune response via viral mimicry.
What are the new findings?
A TE expression score has been developed that is predicative of prognosis in CRC patients where those who have the highest TE score show an immune overdrive phenotype and have the worst prognosis.
The TE expression score predicts prognostic and immune infiltration independent of microsatellite instability and tumor mutation burden (TMB).
Immune response pathways and infiltrate profiles of high TE expression CRC recapitulates those of DNA methyltransferase inhibitor treated cells where TEs are reactivated, suggesting that TE overexpression may drive immune infiltration in CRC.
A pan-cancer analysis found that kidney renal clear cell carcinoma shares are a similar TE expression associated immune overdrive phenotype with adverse prognosis.
How might it impact on clinical practice in the foreseeable future?
Our work highlights the importance of TE expression in evaluating CRC patient prognosis.
The association of TE expression with the immune overdrive phenotype independent of MSI and TMB status suggests that by considering TE expression, there may be new opportunities to identify MSS CRC patients for immunotherapy and develop new strategies to harness TE driven immune response.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by Cancer Genomics Cloud pilot funds provided by Seven Bridges Genomics (XZ) and seed funding from The University of Hong Kong (JWHW).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The University of Hong Kong/Hospital Authority Hong Kong West Cluster. UW 18-599
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
TCGA CRC RNA sequencing data were directly analysed on Cancer Genomics Cloud using a custom pipeline [http://www.cancergenomicscloud.org/]. The processed TE expression for pan-cancer was downloaded from [http://research-pub.gene.com/REdiscoverTEpaper/]. CRC Copy Number GISTIC2 level 4 data was downloaded from Broad GDAC Firehose [http://gdac.broadinstitute.org/runs/analyses_2016_01_28/data/COADREAD/20160128/]. The clinical data, gene program pathways were obtained from [https://xenabrowser.net/]. The TCR/BCR index scores and genetic changes were downloaded from the Supplementary table of the pan-cancer immune landscape paper (PMID: 29628290). Three cell line datasets were downloaded from [https://www.ncbi.nlm.nih.gov/geo/] under the accession number of (i) GSE5816, (ii) GSE80137, and (iii) GSE22250.
